aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit ...
Nature

Distinct type 1 immune networks underlie the severity of restrictive lung disease after COVID-19

The Nature Index 2025 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
Hosted on MSN

Interstitial Lung Disease: Types, Symptoms, Causes, Diagnosis and Treatments

Interstitial Lung Disease: Types, Symptoms, Causes, Diagnosis and Treatments: By Shreoshree Chakrabarty Interstitial Lung Disease (ILD) refers to a group of lung disorders that cause inflammation and ...
The American Journal of Managed Care

Experts Spotlight New Thinking on Restrictive Lung Function at ERS 2025

"Small lung syndrome" is proposed to address persistent low lung volume linked with comorbidities, requiring a new ICD code for accurate diagnosis. Early intervention in lung function trajectories can ...

aTyr Pharma, Inc.: aTyr Pharma Provides Regulatory and Clinical Update for Efzofitimod in Pulmonary Sarcoidosis Following FDA Type C Meeting

Company to continue development of efzofitimod in pulmonary sarcoidosis incorporating FDA feedback. Company plans to submit IND in June 2026 for new Phase 3 study of efzofitimod in patients with chron ...